Cite
HARVARD Citation
Pietanza, M. et al. (n.d.). 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). European journal of cancer. pp. S712-. [Online].